Seek Returns

A vs. EXEL: Agilent vs. Exelixis Stock Comparison

How do Agilent (A) and Exelixis (EXEL) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Exelixis (EXEL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while EXEL is classified in Biotechnology.

Company profile comparison for Agilent (A) and Exelixis (EXEL)
Profile ItemAEXEL
NameAgileThought, Inc. Class A Common StockExelixis Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization49.28 billion USD16.98 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateNovember 18, 1999April 17, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

A
EXEL
GSPC
Loading price history…
Agilent (A) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and Exelixis (EXEL). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and Exelixis (EXEL). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
Total Return (1Y)22.92%74.98%
Total Return (3Y, Annualized)19.33%50.33%
Total Return (5Y, Annualized)3.03%31.10%

Risk Profile

Drawdown History

A
EXEL
GSPC
Loading price history…
Agilent (A) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and Exelixis (EXEL). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
Volatility (1Y, Annualized)33.10%34.17%
Beta (5Y)1.220.41
Max Drawdown (5Y)-38.09%-35.41%
Avg. Volume (3M)2.25M2.33M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and EXEL are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
Sharpe Ratio (1Y)0.562.07
Sortino Ratio (1Y)0.963.23

Profitability

ROE (TTM)

Both Agilent (A) at 20.97% and Exelixis (EXEL) at 44.32% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Agilent (A) at 19.53% and Exelixis (EXEL) at 35.45% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Exelixis (EXEL) at 40.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
ROE (TTM)20.97%44.32%
ROA (TTM)8.63%23.52%
Net Margin (TTM)19.53%35.45%
Operating Margin (TTM)25.56%40.75%
Gross Margin (TTM)53.65%96.26%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and Exelixis (EXEL) at 6.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and Exelixis (EXEL) at 57.95% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
Revenue Growth (YoY)6.73%6.98%
Revenue Growth (3Y CAGR)0.48%12.93%
EPS Growth (YoY)3.16%57.95%
EPS Growth (3Y CAGR)3.02%70.59%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Agilent (A) at 0.56 and Exelixis (EXEL) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
Current Ratio (MRQ)2.053.21
Debt / Equity (MRQ)0.560.09
Net Debt / EBITDA1.15-0.71

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Exelixis (EXEL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
Dividend Yield (TTM)0.59%0.00%
Dividend Payout Ratio (TTM)19.98%0.00%

Valuation

P/E Ratio (TTM)

Both Agilent (A) at 34.47 and Exelixis (EXEL) at 20.83 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Exelixis (EXEL) at 6.80 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Agilent (A) at 6.69 and Exelixis (EXEL) at 9.28 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Agilent (A) vs. Exelixis (EXEL): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Exelixis (EXEL)
MetricAEXEL
P/E Ratio (TTM)34.4720.83
P/S Ratio (TTM)6.686.80
P/B Ratio (MRQ)6.699.28
Free Cash Flow Yield (TTM)2.15%4.47%